Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0	$ 0
Operating expenses:
Research and development	186,342	165,570	125,476
General and administrative	73,317	58,773	41,772
Total operating expenses	259,659	224,343	167,248
Loss from operations	(259,659)	(224,343)	(167,248)
Research and development incentives		500	1,000
Interest expense	(1,875)	(1,862)	(2,977)
Interest and other income, net	5,288	3,889	3,068
Accretion of discount and amortization of premium on investments, net	10,651	(47)	(2,912)
Net loss	$ (245,595)	$ (221,863)	$ (169,069)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.92)	$ (3.26)	$ (2.67)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.92)	$ (3.26)	$ (2.67)
Weighted-average common shares outstanding - basic (in shares)	84,009,004	68,148,925	63,235,417
Weighted-average common shares outstanding - diluted (in shares)	84,009,004	68,148,925	63,235,417